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Abstract
The integration of patient-speciﬁc genomic information into the electronic medical record (EMR) will create many opportunities to
improve patient care. Key to the successful incorporation of genomic information into the EMR will be the development of laboratory
information systems capable of appropriately formatting molecular diagnostic and cytogenetic ﬁndings in the EMR. Due to the lack of
granular genomics-related content in existing medical vocabularies, the adoption of new standards for describing clinically signiﬁcant
genomic information will be an important step toward recognizing the genome-enabled EMR. Appropriate capture of patient-speciﬁc
genomic results in the EMR will generate new opportunities to utilize this information in clinical decision support, including automated
response to pharmacogenomic-based risks.
Ó 2006 Elsevier Inc. All rights reserved.
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Rapid advances in our understanding of the human genome have raised expectations that the delivery of patient care
soon will be improved by these developments. Resources
such as OMIM and PharmGKB [1,2] are useful tools for
retrieving deep information about the clinical and biological
issues involved in a given clinical condition but are not structured to support the operational delivery of patient care.
Despite promising pilot studies [3], the integration of clinical
and genomic information to support the delivery of patient
care is not yet routine. In their current state, electronic medical records (EMRs) and clinical information systems are not
suited to the optimal management of patient-speciﬁc genomic information. Most EMR systems were designed to optimize access to diagnostic results of transient value, such as
blood chemistry results. Genomic results have lifelong value
and (other than those for somatic malignancies) can aﬀect
decision making for family members. Likewise, the unique
biological knowledge associated with genomic ﬁndings is
not currently reﬂected in most existing EMR solutions.
Three developments are necessary for the realization of the
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‘‘Genome-enabled electronic medical record’’ in patient
care: improved tools to support the capture of genomic
results as generated by molecular diagnostic and cytogenetic
methods, a controlled vocabulary appropriate for the
description of clinically signiﬁcant genomic ﬁndings, and
applications capable of enabling clinicians to utilize these
results to support their decision making. Together these
advances will create the foundation upon which genomicsbased capabilities can be built.
Currently, most molecular diagnostics and cytogenetics
laboratories use one of three primary methods to manage
results. One of the most common methods is the use of anatomic pathology reporting systems. These systems manage
text-based reports and are not designed to support the discrete information generated by a genetics laboratory. The
second method is the development of a highly customized
system built using oﬀ-the-shelf software components, often
with in-house software development personnel or consultants. These systems are often diﬃcult to support and are
not readily extensible. The third method is the use of software developed by niche-speciﬁc companies. Such applications typically were not designed to integrate into the
broader clinical systems used by many health care
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Fig. 1. Phases in the development of structured reporting.

organizations. The current oﬀ-the-shelf and niche approaches often do not fully support compliance with the Healthcare
Insurance Portability and Accountability Act (HIPAA). For
example, they frequently lack the ability to log transactions
and queries speciﬁc to a patient record.
The current state of reporting for molecular diagnostic
results is summarized in Fig. 1, in which reporting of
molecular diagnostic ﬁndings is either managed as purely
textual data or, at best, codiﬁed using the limited standards
currently available. There is a need for solutions that satisfy the unique workﬂow requirements of the molecular or
cytogenetics laboratory and capture information in a
method that retains the discrete details of molecular ﬁndings while also supporting the capability of generating a
clear report to the ordering clinician. Among the unique
workﬂow requirements of the molecular diagnostics laboratory is the need to document signiﬁcant amounts of
non-clinical information generated during the processing
of a sample, for example, during DNA isolation or PCR
analysis. An additional requirement is the ability to oﬀer
signiﬁcant ﬂexibility in ordering and canceling tests and
procedures in response to poor quality specimens or other
procedural failures. These systems should also be able to
integrate seamlessly with other laboratory sections, for
example, microbiology or anatomic pathology, in order
to support the interdisciplinary nature of clinical genomics.
For instance, the management of a chronic myelogenous
leukemia (CML) case in the hematopathology section
requires the smooth integration of clinical pathology
(complete blood count) and molecular diagnostic results
(BCR-ABL gene expression levels). At least one supplier
of integrated clinical information systems has released a
laboratory information system module designed to
integrate clinical genomics ﬁndings into the EMR while
also providing the capabilities needed to support the
workﬂow of the molecular diagnostics laboratory.1
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Codiﬁcation of molecular diagnostic or cytogenetic
results using existing medical vocabularies will prove diﬃcult as these lack suﬃcient terms for the description of
molecular ﬁndings. For example, the Systematic Nomenclature of Medicine (SNOMEDÒ) has minimal codes related to the description of molecular diagnostic ﬁndings. The
Logical Observation Identiﬁers Names and Codes
(LOINCÒ) vocabulary has recently added a signiﬁcant
number of molecular pathology terms, but it lacks the rich
context-deﬁning relationships provided by an ontology.
The Clinical Bioinformatics Ontologyä (CBO) addresses
this gap by providing uniquely identiﬁed concepts related
to clinically signiﬁcant molecular ﬁndings [4,5]. The CBO
is a curated ontology that was developed as a semantic network providing relationships that provide greater context
to a codiﬁed term. For example, Fig. 1 shows the association between the gene concept for the RET protooncogene
and relationships to context-deﬁning concepts representing
chromosome 10, the autosomal mode of inheritance and an
amino acid sequence substitution in which the cysteine at
position 609 is substituted for tyrosine. Currently, the
CBO consists of nearly 7000 concepts, each of which is
associated with a global unique identiﬁer, oﬀering the beneﬁts of a controlled vocabulary. These concepts are associated by more than 15,500 relationships. The scope of the
CBO is currently limited to clinical genetics, molecular
pathology, molecular detection, and classiﬁcation of infectious diseases and cytogenetics.
The combination of new laboratory information system
capabilities and the ability to standardize clinical genetics
results to a controlled vocabulary create the capability of
developing novel decision support applications that can
be widely deployed. For instance, codiﬁed result values
describing HIV mutations associated with antiretroviral
drug resistance can be used as the basis for building decision support logic that is embedded in computerized provider order entry (CPOE) systems. This allows the system
to intercept medication orders that are contraindicated by
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genotype results. Extending this concept to other pharmacogenomic associations, such as those between the cytochrome p450 genes and many medications, is a logical
development and will support the movement toward ‘‘personalized medicine.’’
Inclusion of structured family history information (generally lacking in current implementations of clinical information systems) will further extend the possible scope of
genome-enabled decision support. Enhancements to structured clinical documentation tools to better support the
standardized description of family history information will
be a key step toward this goal and will better position systems for the support of family practice. Among the extensions required are improved integration with both existing
and emerging standard vocabularies and integration with
pedigree visualization tools.
Enabling decision support applications to guide providers in determining when a genetic test is warranted will also
be a key beneﬁt of the ‘‘Genome-Enabled Electronic Medical Record.’’ Enabling the system to evaluate the discrete
information stored in a longitudinal medical record will
make the automated recognition of patterns that warrant
further genetic analysis feasible. Finally, genomics is an
area in which the ability to generate new interpretations
of historic results is particularly important as our understanding of the clinical signiﬁcance of single nucleotide
polymorphisms (SNPs) grows. Storage of these results in
a discrete, standardized, format that supports periodic
automated re-analysis will be one of the key beneﬁts of
embedding genomic information in the EMR.
The complexity and dynamic nature of genomic information will require clinical information systems to provide
physicians and other care providers with easy access to reference materials, whether web sites such as Genetests [6] or
abstracts of primary literature such as those provided by
PubMed. Providing access to those resources most appropriate for the case under consideration by the clinician will
be a key requirement in order to ﬁlter the often overwhelming variety of resources.
The operational capture of genomic information during
the delivery of patient care will create new opportunities
for enhancing the discovery process. Subject to IRB
approval and HIPAA compliance requirements, blinded
data warehouses combining traditional clinical and genomic information results can provide a resource for deter-

mining how to prioritize basic research activities,
strengthening the currently weak ‘‘bedside to bench’’ component of translational research, which has been more
focused on ‘‘bench to bedside’’ eﬀorts. Early large-scale
eﬀorts to integrate genomic and clinical information, such
as the work of deCode Genetics in Iceland [7], have relied
on dual entry of clinical information into one system used
to support the delivery of care and another used for
research. This duplication of eﬀort can be reduced as standardization between the systems used in the delivery of
patient care and those used for research purposes is
improved.
Together these developments—the integration of
genomics into the laboratory information system, the
standardization of molecular ﬁndings, and the deployment of clinical applications that simplify the use of
genomic information—will create the foundation for
improvements in the electronic medical record. These
new capabilities must be implemented in software environments fully capable of supporting and enforcing institutional and statutory privacy protections. The successful
development of these enabling technologies will facilitate
improved patient care by enabling physicians to utilize
advanced diagnostic and prognostic capabilities in the
delivery of patient care.
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